PMC9974524_01
Chest x-ray of our patient demonstrating a left sided pleural effusion
cureus-0015-00000034354-i01.jpg
PMC9974524_01_cureus-0015-00000034354-i01.jpg
FIG1
Chest x-ray showed left mid to lower lung field opacification (Figure 1).
Chest CT of our patient demonstrating a left sided pleural effusion
cureus-0015-00000034354-i02.jpg
PMC9974524_01_cureus-0015-00000034354-i02.jpg
FIG2
A CT angiography of the chest showed a moderate to large left-sided pleural effusion with moderate left lower lung compressive atelectasis (Figure 2).
Circled area showing pleural effusion and arrowed area showing calcified endometrial tumor
cureus-0015-00000034354-i03.jpg
PMC9974524_01_cureus-0015-00000034354-i03.jpg
FIG3
There was no evidence of lung parenchymal involvement (Figure 3).
H&E stain of pleural fluid showing large nucleoli, mitotic figures and glands forming high grade adenocarcinoma
cureus-0015-00000034354-i04.jpg
PMC9974524_01_cureus-0015-00000034354-i04.jpg
FIG4
Final pleural fluid analysis showed tumor cells (Figure 4) positive for uterine serous primary carcinoma markers p53 (Figure 5), PAX8 (Figure 6), and P16 and negative for breast markers GATA3, GCDFP15, and mammaglobin, thereby favoring metastatic uterine papillary serous carcinoma.
P53 stain of sample showing many tumor clusters with large nuclei
cureus-0015-00000034354-i05.jpg
PMC9974524_01_cureus-0015-00000034354-i05.jpg
FIG5
Final pleural fluid analysis showed tumor cells (Figure 4) positive for uterine serous primary carcinoma markers p53 (Figure 5), PAX8 (Figure 6), and P16 and negative for breast markers GATA3, GCDFP15, and mammaglobin, thereby favoring metastatic uterine papillary serous carcinoma.
Immunohistochemistry staining of pleural fluid sample for PAX-8 shows positive staining for endometrial cancer, serous subtype
cureus-0015-00000034354-i06.jpg
PMC9974524_01_cureus-0015-00000034354-i06.jpg
FIG6
Final pleural fluid analysis showed tumor cells (Figure 4) positive for uterine serous primary carcinoma markers p53 (Figure 5), PAX8 (Figure 6), and P16 and negative for breast markers GATA3, GCDFP15, and mammaglobin, thereby favoring metastatic uterine papillary serous carcinoma.